Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Suppression of in vitro lymphocyte reactivity by cyclosporin A: existence of a population of drug-resistant cytotoxic lymphocytes

Abstract

Cyclosporin A (CS-A) is an unusual endecapeptide isolated from the fungi Cylindrocarpon lucidum Booth and Tri choderma polysporum1. It is a potent immunosuppressive drug that prevents rejection of kidney2–4 and heart5,6 allografts whilst having a low my elotoxicity7. Its mode of action is still unclear but its main target appears to be the T lymphocyte8. The mixed lymphocyte reaction (MLR) and cell-mediated lymphocytoxicity (CML) used here are generally regarded as in vitro correlates of allograft rejection9. Our data show that CS-A is a powerful inhibitor of MLR reactivity, regardless of whether the cells were obtained from normal or presensitized donors; that the CML of lymph node cells is likewise totally inhibited if the drug is added early during cell culture; and that, by contrast, the cytotoxic response of spleen cells from presensitized but not from normal mice is only partially inhibited, even with a tenfold increase in dose. It is therefore suggested that there exists a population of cytotoxic spleen cells that is relatively resistant to the action of this drug.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Dreyfuss, M. et al. Eur. J. appl. Microbiol. 3, 125–133 (1976).

    Article  CAS  Google Scholar 

  2. Calne, R. Y. & White, D. J. G. IRCS J. med. Sci. 5, 595 (1977).

    CAS  Google Scholar 

  3. Greene, C. J. & Allison, A. G. Lancet i, 1182–1183 (1978).

    Article  Google Scholar 

  4. Calne, R. Y. et al. Lancet iiI, 1323–1327 (1978).

    Article  Google Scholar 

  5. Calne, R. Y. et al. Lancet i, 1183–1185 (1978).

    Article  Google Scholar 

  6. Jamieson, S. W. et al. Lancet i, 545 (1979).

    Article  Google Scholar 

  7. Borel, J. F., Feurer, C., Gubler, H. U. & Stahelin, H. Agents Actions 6, 468–475 (1976).

    Article  CAS  Google Scholar 

  8. Brent, L. Transplantn Proc. 12, 234–243 (1980).

    Google Scholar 

  9. Häyry, P., Andersson, L. C., Nordling, S. & Virolainen, H. Transplantn. Rev. 12, 91–140 (1972).

    Google Scholar 

  10. Cooley, M. A. Scand. J. Immun. 7, 371–380 (1978).

    Article  CAS  Google Scholar 

  11. Kuperman, O. J. & Bach, F. J. Scand. J. Immun. 6, 161–172 (1977).

    Article  CAS  Google Scholar 

  12. Simpson, E., O'Hopp, S. & Wunderlich, J. Transplantation 18, 374–377 (1974).

    Article  CAS  Google Scholar 

  13. Leoni, P., Garcia, R. C. & Allison, A. C. J. clin. Lab. Immun. 1, 67–72 (1978).

    CAS  Google Scholar 

  14. White, D. J. G., Plumb, A. M., Pawelec, G. & Brons, G. Transplantation 27, 55–58 (1979).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Horsburgh, T., Wood, P. & Brent, L. Suppression of in vitro lymphocyte reactivity by cyclosporin A: existence of a population of drug-resistant cytotoxic lymphocytes. Nature 286, 609–611 (1980). https://doi.org/10.1038/286609a0

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/286609a0

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing